158 related articles for article (PubMed ID: 9185691)
1. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U
Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691
[TBL] [Abstract][Full Text] [Related]
2. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay.
Griffioen M; Borghi M; Schrier PI; Osanto S
Int J Cancer; 2001 Aug; 93(4):549-55. PubMed ID: 11477559
[TBL] [Abstract][Full Text] [Related]
3. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
4. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
5. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.
Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U
Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676
[TBL] [Abstract][Full Text] [Related]
6. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
7. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
[TBL] [Abstract][Full Text] [Related]
8. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.
Letsch A; Keilholz U; Schadendorf D; Nagorsen D; Schmittel A; Thiel E; Scheibenbogen C
Int J Cancer; 2000 Sep; 87(5):659-64. PubMed ID: 10925359
[TBL] [Abstract][Full Text] [Related]
9. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
10. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Asai T; Storkus WJ; Whiteside TL
Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
[TBL] [Abstract][Full Text] [Related]
13. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
14. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
[TBL] [Abstract][Full Text] [Related]
15. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
16. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
17. Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.
Schmittel A; Keilholz U; Max R; Thiel E; Scheibenbogen C
Int J Cancer; 1999 Jan; 80(1):39-43. PubMed ID: 9935227
[TBL] [Abstract][Full Text] [Related]
18. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
19. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.
Janetzki S; Song P; Gupta V; Lewis JJ; Houghton AN
J Immunol Methods; 2000 Feb; 234(1-2):1-12. PubMed ID: 10669764
[TBL] [Abstract][Full Text] [Related]
20. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
